drugset / Trial / NCT03544021
CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia （ALL）
Phase 1/2
Unknown
10 enrolled
The Affiliated Hospital of the Chinese Academy of Military Medical Sciences
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety and efficiency of CD19-Targeted CAR-T in Treating Patients with relapsed/refractory acute leukemia.
Timeline
- Start
- 2018-03-01
- Primary completion
- 2019-03-01
- Completion
- 2020-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Tisagenlecleucel | Cell therapy | — | Other |